AN OPEN-LABEL STUDY OF OLEZARSEN (ISIS 678354) ADMINISTERED SUBCUTANEOUSLY TO PEDIATRIC PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)

Registry ID

ISIS 678354-CS21

Source registry

HEALTH_CANADA

Status

Pending

Study type

INTERVENTIONAL

Sponsor

IONIS PHARMACEUTICALS INC

Last update

2025-10-06

Conditions

• FAMILIAL CHYLOMICRONEMIA SYNDROME

Related clinical trials

• AN OPEN-LABEL SAFETY STUDY OF AKCEA-APOCIII-LRX ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) PREVIOUSLY TREATED WITH VOLANESORSEN (ISIS 304801)
• AN OPEN-LABEL EXTENSION STUDY OF AKCEA-APOCIII-LRX ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)

View on source registry